Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P K Paik

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
'Genotype/immunotype' correlations in resected NSCLCP K Paik, M D Hellmann
Annals of the Rheumatic Diseases|October 13, 2005
Diagnosis and management of adult onset Still's diseaseP Efthimiou, P K Paik, L Bielory
Molecular and Cellular Biology|September 22, 1999
The oncogenic 70Z Cbl mutation blocks the phosphotyrosine binding domain-dependent negative regulation of ZAP-70 by c-Cbl in Jurkat T cellsJ E van Leeuwen, P K Paik, L E Samelson
The Journal of Biological Chemistry|February 13, 1999
Activation of nuclear factor of activated T cells-(NFAT) and activating protein 1 (AP-1) by oncogenic 70Z Cbl requires an intact phosphotyrosine binding domain but not Crk(L) or p85 phosphatidylinositol 3-kinase associationJ E van Leeuwen, P K Paik, L E Samelson
ESMO Open|April 9, 2025
Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphomaU M Lauer, A Awada, S Postel-Vinay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersJ K Sabari, G C Leonardi, C A Shu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2020
COVID-19 in patients with lung cancerJ Luo, H Rizvi, I R Preeshagul, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2017
'Genotype/immunotype' correlations in resected NSCLCP K Paik, M D Hellmann
Annals of the Rheumatic Diseases|October 13, 2005
Diagnosis and management of adult onset Still's diseaseP Efthimiou, P K Paik, L Bielory
Molecular and Cellular Biology|September 22, 1999
The oncogenic 70Z Cbl mutation blocks the phosphotyrosine binding domain-dependent negative regulation of ZAP-70 by c-Cbl in Jurkat T cellsJ E van Leeuwen, P K Paik, L E Samelson
The Journal of Biological Chemistry|February 13, 1999
Activation of nuclear factor of activated T cells-(NFAT) and activating protein 1 (AP-1) by oncogenic 70Z Cbl requires an intact phosphotyrosine binding domain but not Crk(L) or p85 phosphatidylinositol 3-kinase associationJ E van Leeuwen, P K Paik, L E Samelson
ESMO Open|April 9, 2025
Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphomaU M Lauer, A Awada, S Postel-Vinay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2018
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancersJ K Sabari, G C Leonardi, C A Shu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 21, 2020
COVID-19 in patients with lung cancerJ Luo, H Rizvi, I R Preeshagul, et al.
Pageof 1